Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $65.85 in the prior trading day, Arcellx Inc (NASDAQ: ACLX) closed at $65.39, down -0.70%. In other words, the price has decreased by -$0.70 from its previous closing price. On the day, 0.83 million shares were traded. ACLX stock price reached its highest trading level at $66.73 during the session, while it also had its lowest trading level at $63.625.
Ratios:
Our goal is to gain a better understanding of ACLX by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.16 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 987.69. For the most recent quarter (mrq), Quick Ratio is recorded 4.29 and its Current Ratio is at 4.29. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Redburn Atlantic on October 08, 2024, initiated with a Buy rating and assigned the stock a target price of $109.
On May 31, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $70.Piper Sandler initiated its Overweight rating on May 31, 2024, with a $70 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 14 ’25 when Patel Kavita sold 1,500 shares for $65.87 per share. The transaction valued at 98,801 led to the insider holds 0 shares of the business.
Heery Christopher sold 4,230 shares of ACLX for $319,485 on Jan 07 ’25. The CHIEF MEDICAL OFFICER now owns 28,638 shares after completing the transaction at $75.53 per share. On Jan 08 ’25, another insider, Heery Christopher, who serves as the CHIEF MEDICAL OFFICER of the company, sold 3,553 shares for $73.69 each. As a result, the insider received 261,831 and left with 25,085 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACLX now has a Market Capitalization of 3535944704 and an Enterprise Value of 3027020544. For the stock, the TTM Price-to-Sale (P/S) ratio is 22.69 while its Price-to-Book (P/B) ratio in mrq is 7.31. Its current Enterprise Value per Revenue stands at 19.427 whereas that against EBITDA is -46.356.
Stock Price History:
The Beta on a monthly basis for ACLX is 0.26, which has changed by 0.048233032 over the last 52 weeks, in comparison to a change of 0.24440956 over the same period for the S&P500. Over the past 52 weeks, ACLX has reached a high of $107.37, while it has fallen to a 52-week low of $47.88. The 50-Day Moving Average of the stock is -20.12%, while the 200-Day Moving Average is calculated to be -5.77%.
Shares Statistics:
The stock has traded on average 627.66K shares per day over the past 3-months and 801720 shares per day over the last 10 days, according to various share statistics. A total of 53.99M shares are outstanding, with a floating share count of 40.71M. Insiders hold about 24.71% of the company’s shares, while institutions hold 81.57% stake in the company. Shares short for ACLX as of 1735603200 were 5809082 with a Short Ratio of 9.26, compared to 1732838400 on 5226452. Therefore, it implies a Short% of Shares Outstanding of 5809082 and a Short% of Float of 12.3.
Earnings Estimates
The market rating of Arcellx Inc (ACLX) is currently shaped by the ongoing analysis conducted by 13.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.7, with high estimates of -$0.46 and low estimates of -$1.06.
Analysts are recommending an EPS of between -$0.84 and -$2.01 for the fiscal current year, implying an average EPS of -$1.5. EPS for the following year is -$2.24, with 15.0 analysts recommending between $0.82 and -$3.9.
Revenue Estimates
14 analysts predict $25.69M in revenue for the current quarter. It ranges from a high estimate of $41.7M to a low estimate of $17.3M. As of the current estimate, Arcellx Inc’s year-ago sales were $63.15MFor the next quarter, 14 analysts are estimating revenue of $21.21M. There is a high estimate of $27.5M for the next quarter, whereas the lowest estimate is $14.9M.
A total of 17 analysts have provided revenue estimates for ACLX’s current fiscal year. The highest revenue estimate was $165M, while the lowest revenue estimate was $110M, resulting in an average revenue estimate of $121.71M. In the same quarter a year ago, actual revenue was $110.32MBased on 17 analysts’ estimates, the company’s revenue will be $119.48M in the next fiscal year. The high estimate is $285.25M and the low estimate is $59.5M.
